Isofol Medical AB (OSTO:ISOFOL)

kr 0.725 -0.005 (-0.68%) Market Cap: 117.10 Mil Enterprise Value: -27.13 Mil PE Ratio: 0 PB Ratio: 1.04 GF Score: 33/100

Q4 2022 Isofol Medical AB (publ) Earnings Call Transcript
Feb 22, 2023

kr0.627 (-0.63%)

Earnings
Q3 2022 Isofol Medical AB (publ) Earnings Call Transcript
Nov 11, 2022

kr0.692 (-1.28%)

Earnings
Q2 2022 Isofol Medical AB (publ) Earnings Call Transcript
Aug 23, 2022

kr1.22 (+0.50%)

Earnings
Q1 2022 Isofol Medical AB (publ) Earnings Call Transcript
May 12, 2022

kr8 (-2.44%)

Earnings
Isofol Medical AB (publ) Data Analysis of Phase III Agent Study Transcript
Apr 22, 2022
Q4 2021 Isofol Medical AB (publ) Earnings Call Transcript
Feb 24, 2022

kr8.09 (-1.10%)

Earnings

Isofol Medical AB (publ) Data Analysis of Phase III Agent Study Transcript

Apr 22, 2022 / 01:00PM GMT

Release Date Price: kr9 (-1.64%)

Transcript

Ulf Jungnelius

Isofol Medical AB - CEO

Thank you and good afternoon, everybody that's on the line. I've probably sent out the press release that we are now starting the analysis process that will lead to the unblinding and data out of that study.

But let's go to slide four and a little bit about the background to our announcement. So, last year in December, we identified that we had more patients than anticipated that were censored without having a documented tumor progression. And the reason for the censoring was that many of them had started a new therapy without having a progression, which was again violation of the protocol.

The consequence is that we did not reach the prespecified number of progression for the event that was needed as a milestone for us to start the unblinding process. As the company is unblinded to the study, this is a blinded study where we don't know what's going on in this study. So, this concept is completely blinded. The physicians know what patients we are receiving. And so, there is no safety issue for patients.

And we've had seven independent

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.